IO Biotech completes enrollment in Phase 2 trial of IO102-IO103

IO Biotech (IOBT) announced it has completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial, IOB-032/PN-E40. The trial is studying IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda, given before and after surgery with curative intent in patients with resectable melanoma or squamous cell carcinoma of the head and neck. “We are pleased to have completed enrollment early in this study, as it signifies an important step in exploring the potential of our investigational therapeutic cancer vaccine, IO102-IO103, across a range of solid tumors at an earlier stage of disease progression,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “Our off-the-shelf cancer vaccine is designed to be a readily available option for patients and has demonstrated encouraging clinical activity without significant systemic toxicity across three first line advanced cancer indications – melanoma, lung cancer and head and neck cancer. With data from our Phase 3 trial in patients with advanced melanoma expected in the first half of 2025 and initial data from this Phase 2 basket trial also expected in 2025, we hope to add to the accumulating evidence of potential benefit of this combination therapy across a range of difficult-to-treat cancers.”